Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2024
Date Filed: May 22, 2024
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate governance and regulatory notifications rather than financial performance data.
Material Changes
The primary material event disclosed in this filing is the cessation of securities for the ticker symbol "ATH," as detailed in Exhibit 99.1. No other material changes to financial position or operations are described in the provided text.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. The document serves primarily to incorporate the notification of the cessation of securities by reference into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the status and implications of the "ATH" ticker symbol cessation referenced in Exhibit 99.1.
- Confirm the impact of the cessation on the company's existing Registration Statements (Form S-8 and Form F-3).
- Review the company's latest Form 20-F for detailed financial statements, as this Form 6-K does not include them.